---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-026282"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2026-08-06T20:19:37+00:00"
generated_at: "2026-08-06T20:22:41.551199+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Puma Biotech Q2 net income $8.2M, raises 2026 guidance on NERLYNX demand

## Summary
- Q2 product revenue $53.6M (+9% YoY); GAAP net income $8.2M ($0.16/sh) vs $5.9M ($0.12/sh) in Q2 2025.
- Non-GAAP adjusted net income $10.1M ($0.20/sh basic) vs $7.5M ($0.15/sh) prior year.
- Raises FY 2026 net product revenue guidance to $205-209M (prior $202-206M); net income to $17-20M (prior $16-19M).
- Debt fully repaid in May 2026; cash & securities $93.9M at June 30, 2026.
- R&D expenses rose $9.4M YTD on alisertib trial activity; milestones include ALISCA-Lung2 initiation in Q3 2026.

## SEC filing metadata
- accession: 0001437749-26-026282
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2026-08-06T20:19:37+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774926026282/0001437749-26-026282-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774926026282/pbyi20260608_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-026282
- JSON: https://secwatch.observer/filing/0001437749-26-026282.json
- Plain text: https://secwatch.observer/filing/0001437749-26-026282.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.